Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEREMI: Ceftriaxone vs Cefotaxime on Intestinal Microbiota Resistance
NCT02659033Phase 3
Key facts
- Status
- Completed
- Start
- Mar 2016
- Primary completion
- Mar 2016
- Countries
- 1
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Modality
- Reversible Covalent Inhibitors
- Conditions
- bacterial infection
01
Overview
Phase 3, randomised, open-label trial of ceftriaxone and cefotaxime in bacterial infection, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: The area under the curve of the 3rd generation cephalosporins resistant enterobacteria in the intestinal microbiota between D0 and D7. Started Mar 2016; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Healthy volunteers aged 18-65 with normal BMI and no recent antibiotic use or hospitalization.
04
Endpoints
Primary
The area under the curve of the 3rd generation cephalosporins resistant enterobacteria in the intestinal microbiota between D0 and D7
Beyond the preview
Go deeper on NCT02659033.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659033.